Voglibose 0.3 mg + Repaglinide 1 mg

Category- Allopathy

Medicine Highlights

Voglibose + Repaglinide Uses

Voglibose + Repaglinide tablets are a combination medicine used to help control blood sugar levels in Type 2 diabetes mellitus condition.     

Voglibose + Repaglinide side effects 

More Common  

1. Low blood sugar (hypoglycemia) 
2. Stomach pain or discomfort 
3. Gas / bloating 
4. Diarrhea or loose stools 
5. Nausea 
6. Headache 
7. Dizziness                

Less Common 

1. Severe low blood sugar (sweating, shakiness, confusion, fainting) 
2. Severe allergic reactions (rash, swelling, difficulty breathing) 
3. Liver problems (yellowing of skin/eyes, dark urine) 
4. Weakness or unusual tiredness            

How Voglibose + Repaglinide works 

Repaglinide helps your pancreas release more insulin quickly after meals, which lowers blood sugar levels. Voglibose slows down the breakdown and absorption of carbohydrates in the intestine, so sugar enters the blood more slowly after eating. Together, they help prevent sudden rises in blood sugar after meals and improve diabetes control. 

Safety Measures and Warning 

Allergy or Hypersensitivity

People allergic to this medication are not recommended to take this medicine as it can cause serious allergic reactions like rash, swelling, or trouble breathing, always ask your doctor first.

Type 1 diabetes or diabetic ketoacidosis

This medicine is not used for type 1 diabetes or diabetic ketoacidosis and should not be taken in these conditions.

Severe liver or kidney problems

If you have liver or kidney disease, this medicine may not be processed properly in the body, which can increase the risk of side effects. Always consult your doctor before taking it.

Severe digestive disorders

Voglibose may worsen bowel problems like intestinal blockage, severe digestion issues, or chronic bowel disease. Always consult your doctor first. 

Pregnancy

This medicine should only be taken if clearly needed during pregnancy, because it may affect blood sugar levels and its safety may not be fully established in all cases. Always consult your doctor before taking it.

Breastfeeding women

This medicine should be used with caution while breastfeeding, as small amounts may pass into breast milk or affect the mother’s blood sugar levels, which may indirectly affect feeding and overall health. Always consult your doctor before taking it.

Voglibose + Repaglinide Interaction with Food Product 

There are no major food restrictions, but this medicine works best when taken before meals. Avoid skipping meals after taking it, as this may cause low blood sugar. It is also better to avoid excessive sugary foods, as they can reduce the benefit of the medicine. 

Voglibose + Repaglinide Interaction with Other Medicines  

Avoid taking Voglibose + Repaglinide with the following medicines, as it may increase or decrease the desired effect, or in worse cases, it could be fatal:

Voglibose + Repaglinide Chemical Structure

IUPAC (International Union of Pure and Applied Chemistry)/ Chemical name

Voglibose: (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol 

Repaglinide: 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid 

Intake routine/cycle

Daily dose

Take Voglibose + Repaglinide exactly as your doctor recommends. The dose may change based on your condition and how well you respond. Do not take more than prescribed without consulting your doctor.

Missed Dose

If you forget to take your medicine, take the medication as soon as you remember. If it’s nearly time for your next dose, skip the missed one and continue with your regular schedule. Always consult the doctor before making any changes to your dosage.

Overdose

It is not recommended to take more than the prescribed dose of Voglibose + Repaglinide tablets. Taking too much can increase the risk of severe low blood sugar, dizziness, sweating, shakiness, confusion, or fainting. If you notice any unusual symptoms or feel unwell after taking the medicine, seek immediate medical attention. 

Storage

1. Store the medicine at room temperature. 
2. Keep away from sunlight and moisture. 
3. Keep out of reach of children. 

Directions for use 

1. Take this medicine exactly as prescribed by your doctor, at the same time each day. 
2. Do not stop taking this medicine without your doctor’s approval, even if you feel better. 
3. If you forget to take this medicine, take it as soon as you remember. If it’s almost time for your next dose, skip the missed dose.  

Voglibose + Repaglinide Summary 

Voglibose 0.3 mg + Repaglinide 1 mg is a combination medicine used to control blood sugar levels in people with type 2 diabetes mellitus. Repaglinide helps the pancreas release more insulin after meals, while Voglibose slows down the digestion and absorption of carbohydrates in the intestine. Together, they help reduce the rise in blood sugar after eating and improve overall blood sugar control. 

This medicine is usually prescribed along with a healthy diet, exercise, and regular blood sugar monitoring. It is especially helpful for controlling post-meal sugar spikes. 

Common side effects may include low blood sugar, stomach discomfort, gas, bloating, diarrhea, nausea, headache, or dizziness. Rare but serious side effects include severe hypoglycemia, allergic reactions, or liver problems. The medicine should be taken exactly as prescribed, usually before meals. Patients should consult their doctor before use, especially if they have liver, kidney, or digestive problems, are pregnant, or are taking other medications.  

FAQ’s

What are the uses of Voglibose? 

Voglibose is used to treat type 2 diabetes mellitus. It helps control high blood sugar after meals by slowing down the digestion and absorption of carbohydrates in the intestine. It is usually given along with diet, exercise, and other diabetes medicines to improve blood sugar control. 

How does Voglibose work? 

Voglibose works by slowing down the breakdown of carbohydrates into glucose in the intestine. This delays the absorption of sugar into the blood after eating, which helps reduce post-meal blood sugar spikes and improves overall diabetes control. 

What drug class does Voglibose belong to? 

Voglibose belongs to the class of medicines called alpha-glucosidase inhibitors. These medicines help lower blood sugar by slowing carbohydrate digestion in the intestine. 

How does Repaglinide work? 

Repaglinide works by stimulating the pancreas to release more insulin, especially around meal times. This extra insulin helps move sugar from the blood into the body’s cells, which lowers blood sugar levels after meals. 

What is the usual daily dose of Repaglinide? 

The usual dose of Repaglinide is decided by the doctor based on blood sugar levels and response to treatment. It is usually taken before meals, often 1 to 4 mg per dose, and may be taken 2 to 4 times a day depending on meals. The maximum recommended daily dose is usually 16 mg per day. Always take it exactly as prescribed by your doctor. 

Reference 

1. PubChem. Voglibose [Internet]. Nih.gov. PubChem; 2026 [cited 2026 Apr 3]. Available from 
2. Voglibose: An Alpha Glucosidase Inhibitor. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2013;  
3. Voglibose [Internet]. go.drugbank.com. Available from 
4. PubChem. Repaglinide [Internet]. Nih.gov. PubChem; 2024. Available from 
5. Milner Z, Akhondi H. Repaglinide [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from 
6. Repaglinide (Oral Route) Description and Brand Names – Mayo Clinic [Internet]. www.mayoclinic.org. Available from 

Pranathi Chintaluri

Pranathi is a final year Pharm D student at Chalapathi Institute of Pharmaceutical Sciences. She loves learning and applying her knowledge in pharmacy and has a passion for writing, which allows her to express ideas clearly and creatively. She enjoys combining her technical skills with her love for writing and communication to make a meaningful impact. Currently she is working on a research paper about “Consanguineous marriages and its impact on children’s health” which will be published by the end of 2025.